TransMedics Group, Inc. (TMDX) — ESG & Values Scores

Environment story

TransMedics discloses minimal environmental data. No Scope 1, Scope 2, or Scope 3 emissions figures are reported in the 10-K. No net-zero target year is disclosed. The company operates manufacturing and R&D facilities in Andover, Massachusetts and Mirandola, Italy, and operates a fleet of 22 fixed-wing aircraft for organ transportation logistics, creating operational carbon exposure through fuel consumption and electricity use. No documented renewable energy commitments, carbon offset programs, or environmental controversies are disclosed. The lack of quantifiable environmental metrics prevents detailed scoring but the expansion of aviation operations introduces carbon intensity that is not addressed in available disclosures.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Facility Operations

Operates manufacturing facility in Andover, Massachusetts and R&D facility in Mirandola, Italy; planned relocation to new headquarters in Somerville, Massachusetts by January 2028.
Aircraft Fleet Operations

Acquired 22 fixed-wing aircraft and operates aviation logistics network as part of National OCS Program; relies on Pratt & Whitney engines.

Direct carbon emissions from aviation fuel consumption; no mitigation strategy disclosed.

Social story

TransMedics reports 898 total employees as of December 31, 2025, with most located in the United States. No diversity metrics (gender, racial, or ethnic breakdown) are disclosed in the 10-K. No CEO-to-median-worker pay ratio is provided. No documented labor disputes, union-suppression activities, strikes, or NLRB complaints are disclosed. The company emphasizes attraction and retention of specialized personnel (surgeons, clinical specialists, pilots, engineers) and notes competitive compensation pressures. Supply chain audits and human-rights risk assessments are not disclosed. No formal diversity, equity, and inclusion program disclosures or supplier-diversity initiatives are evident in the filing. The company's social profile is largely opaque due to minimal disclosure.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Personnel Recruitment and Retention

Company focuses on recruiting, training and retaining qualified surgeons, clinical specialists, pilots and technical personnel; acknowledges competitive compensation pressures and notes need to increase compensation to attract talent.

Potential positive labor practices through focus on training, but no formal diversity or equity commitments disclosed.
Training Programs

Operates clinical training facility in Andover, Massachusetts for customer education and employee certification on OCS use.

Governance story

TransMedics provides limited governance disclosures in the 10-K. Board independence percentage, share structure (single vs. dual-class), and specific board composition are not detailed in the provided excerpt. No lobbying expenditures are disclosed. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings are mentioned. The company identifies a material weakness in internal control over financial reporting that has been previously disclosed. The company has engaged outside ex-FDA regulatory advisors and maintains compliance programs for fraud and abuse laws (Anti-Kickback Statute, False Claims Act). An activist short seller published a disparaging report and filed a petition with the FDA requesting suspension of OCS PMA approval, citing alleged off-label use; the company has responded with legal and factual rebuttal. No significant governance controversies or fines are disclosed in available materials.

Criticisms on file

Activist Short Seller Petition to FDA
Source: TransMedics 10-K Risk Factors: 'An activist short seller published a disparaging report about our business...this activist short seller has submitted a petition to the FDA, requesting that the FDA suspend the PMA approval for the OCS and take other adverse actions related to the OCS, and in particular the OCS Liver, due to alleged off-label use of the device.'

Disclosed initiatives

Regulatory Compliance Program

Company implements compliance programs addressing Anti-Kickback Statute, False Claims Act, healthcare fraud statutes, and international healthcare laws; provides compliance training and guidance to customers.

Demonstrates commitment to healthcare fraud prevention and transparency.
Intellectual Property and Legal Counsel

Maintains patent portfolio of ~451 issued patents and pending applications; engages outside legal counsel and ex-FDA regulatory advisors for regulatory strategy.
Internal Controls

Company has disclosed a material weakness in internal control over financial reporting.

Negative impact on governance confidence; indicates control deficiencies requiring remediation.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of TransMedics Group, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open TransMedics Group, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)